AstraZeneca Pharmaceuticals LP

2725 articles with AstraZeneca Pharmaceuticals LP

• 

  AstraZeneca Notches Back-to-Back Late-Stage Wins in Lung Cancer

  3/9/2023

  AstraZeneca reported positive data from both the Phase III ADAURA trial studying Tagrisso (osimertinib) and the Phase III AEGEAN studying Imfinzi (durvalumab) in NSCLC patients.

• Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

  3/7/2023

  Personalis, Inc. (Nasdaq: PSNL) today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

• ENHERTU® Showed Clinically Meaningful and Durable Responses Across Multiple HER2 Expressing Tumor Types in DESTINY-PanTumor02 Phase 2 Trial

  3/6/2023

  Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZeneca’s ENHERTU® met the pre-specified target for objective response rate and demonstrated durable response across multiple HER2 expressing advanced solid tumors in heavily pre-treated patients.

• Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023

  3/2/2023

  Alexion, AstraZeneca Rare Disease, will showcase the potential for its pioneering therapies to redefine the treatment landscape for certain rare neurological diseases at the American Academy of Neurology Annual Meeting, April 22-27, 2023.

• Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  3/2/2023

  AstraZeneca and Merck (NYSE: MRK) today announced that the U.S. Food and Drug Administration (FDA) will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental new drug application (sNDA) for use of LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

• 

  AstraZeneca Rare Disease R&D Expansion Adds 500 Jobs At New Hub

  2/28/2023

  On Rare Disease Day, Feburary 28, AstraZeneca announced the creation of the Alexion, AstraZeneca Rare Disease Development Hub in Toronto, Ontario.

• ASTRAZENECA ANNOUNCES MAJOR INVESTMENT IN ONTARIO'S LIFE SCIENCES SECTOR

  2/27/2023

  AstraZeneca is pleased to announce it is bringing 500 highly-skilled scientific and high-tech jobs to the Greater Toronto Area (GTA) in a major expansion of its research footprint in Canada. 

• Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901

  2/23/2023

  Keymed Biosciences Inc., and Lepu Biopharma Co., Ltd, jointly announce a global exclusive licence agreement with AstraZeneca for CMG901, a potential first-in-class Claudin 18.2 antibody drug conjugate.

• 

  Pfizer Gains on Astra and Sanofi in Infant RSV Prevention Race

  2/21/2023

  The FDA accepted the BLA for and granted Pfizer's maternal RSV vaccine candidate priority review.

• Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium

  2/16/2023

  AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of the key secondary endpoint of overall survival (OS) from the Phase 3 PROpel trial evaluating LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred), compared to placebo plus abi/pred.

• AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium

  2/16/2023

  Results from the final prespecified overall survival (OS) analysis of the PROpel Phase III trial in metastatic castration-resistant prostate cancer (mCRPC) showed LYNPARZA® (olaparib), jointly developed and commercialized by AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada in combination with abiraterone and prednisone or prednisolone demonstrated median OS of 42.1 months versus 34.7 months for abiraterone plus placebo.

• Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

  2/14/2023

  Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported today that rilvegostomig, AstraZeneca's bi-specific antibody derived from Compugen's COM902, is expected to progress into Phase 3 this year.

• 

  AstraZeneca Spin-off Aristea Folds After Safety Issues End Lead Program

  2/13/2023

  Due to safety concerns, Aristea Therapeutics announced Friday that it was discontinuing the development of its Phase II lead program. As a result, the San Diego-based biotech is also dissolving its business.

• SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development

  2/13/2023

  SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a leading cloud-native global data-sharing network and health analytics platform, is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.

• 

  Another IL-12 Candidate Bites the Dust as AstraZeneca Shifts Focus

  2/9/2023

  AstraZeneca announced it is making significant cuts from its pipeline in an attempt to realign its priorities and recover from waning COVID-19 drug sales. 
• 

  Roche Goes Toe-to-Toe with AstraZeneca’s Soliris in PNH

  2/7/2023

  Data from a Phase III study show Genentech’s crovalimab is non-inferior to AstraZeneca’s Soliris, the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).

• TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

  2/2/2023

  AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

  2/2/2023

  Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

  1/17/2023

  AIM ImmunoTech Inc. announced it has entered into an external sponsored collaborative clinical research agreement with Erasmus MC and AstraZeneca.

• CinCor Pharma to be Acquired by AstraZeneca

  1/9/2023

  CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.